Comparison of functional and cognitive donepezil effects in Alzheimer's disease

Kathleen Saine, C. Munro Cullum, Kristin Martin-Cook, Linda Hynan, Doris A. Svetlik, Myron F. Weiner

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Donepezil has been shown to improve aspects of cognitive functioning in persons with Alzheimer's disease (AD), but its impact on instrumental activities of daily living has received little attention. In a within-subject design, 24 community-dwelling persons with AD were treated with open-label donepezil over a 12-month period. To assess functional abilities, a brief, objective measure of instrumental activities of daily living skills was used (Texas Functional Living Scale; TFLS). Global cognitive abilities were assessed with the Mini-Mental State Examination (MMSE). Changes in TFLS and MMSE scores were much the same. Improvements on the TFLS and MMSE were seen over a 3-month period. At 12 months, both TFLS and MMSE scores declined slightly below baseline. These results support an effect of donepezil on cognitive measures and day-to-day function and also suggest that the MMSE reflects well the actual functional ability of persons with moderate AD.

Original languageEnglish (US)
Pages (from-to)181-185
Number of pages5
JournalInternational Psychogeriatrics
Issue number2
StatePublished - Jun 2002


  • Alzheimer's disease
  • Cognitive function
  • Donepezil
  • Texas Functional Living Scale

ASJC Scopus subject areas

  • Clinical Psychology
  • Gerontology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health


Dive into the research topics of 'Comparison of functional and cognitive donepezil effects in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this